Key points from article :
Genflow Biosciences Plc, a biotechnology company focused on longevity research, has successfully raised £715,000 through the sale of shares.
This money will be used to fund the company's further research and clinical trials. They plan to develop treatments for age-related diseases, specifically focusing on a potential cure for the liver disease NASH.
The funding was raised by selling new company shares to investors, including a significant investment from the CEO, Dr. Eric Leire.
Genflow Biosciences is led by Dr. Eric Leire, and all company directors participated in the funding round.
The successful fundraising shows increasing interest in aging research from UK institutional investors.
Genflow Biosciences is headquartered in the UK with research facilities in Belgium. The fundraising announcement was published through the London Stock Exchange.
